BMJ Open Impact Factor

BMJ Open's 2.5 JIF is not a prestige signal in the way The BMJ, JAMA, The Lancet, or NEJM use impact factor. It is a credibility signal for broad, methodologically sound clinical research that needs open access, PubMed/MEDLINE visibility, and a transparent review record. That is why the number can be useful even though it is modest.

The author decision is not "is 2.5 high enough?" The better question is whether the paper benefits from BMJ Open's model. A pragmatic observational study, protocol, systematic review, qualitative paper, or health-services analysis can fit BMJ Open better than a higher-JIF specialty journal if the value comes from clinical transparency and broad medical indexing. A mechanistic discovery, small case series, or practice-changing RCT usually belongs somewhere else.

The current 27% acceptance rate also changes the risk calculation. BMJ Open is accessible compared with elite general-medicine journals, but it is not an automatic outlet. The methods, reporting checklist, ethics statement, data availability language, and open-review posture still decide whether the paper survives the first editorial read.

The BMJ Open impact factor is 2.5 for the 2025 Journal Impact Factor in the 2026 Journal Citation Reports release. That makes it one of the lower-impact medical journals that researchers commonly search for, but the number alone does not tell you whether BMJ Open is the right target for your manuscript. Use this page for the JIF, 5-year JIF, Q2 rank, CiteScore, SJR, and related citation-metric context; use the acceptance-rate page only when the question is selectivity.

Source: current BMJ and Journal Citation Reports metric context for the 2026 release and 2025 data, with older rows treated as public-history planning context. Verify exact historical values in Clarivate Journal Citation Reports before formal citation.

BMJ Open's current About page lists CiteScore 4.1, CiteScore rank 129/669, and SJR 0.93. These secondary metrics still support broad clinical visibility, but they should be verified in Scopus or SCImago before formal use because BMJ's author-facing metric snippets can lag the journal About panel.

The COVID-era spike to 4.4 in 2021 was driven by heavily cited pandemic-related research. BMJ Open published a large volume of COVID observational studies, many of which accumulated citations rapidly. The current JIF is up from 2.4 in the 2023 data year and flat versus 2.5 in the 2024 data year, which is stabilization rather than a decline in journal quality.

The five-year JIF of 2.8 smooths over annual noise and gives a more accurate picture. BMJ Open has been remarkably consistent in the 2.3-2.8 range outside the pandemic years.

In our BMJ Open submission-readiness reviews, three editorial flags drive early rejection or a weak first review most frequently.

Reporting guideline compliance claimed but not implemented in the text.

BMJ Open's author instructions state: "All manuscripts reporting clinical trials should include a CONSORT flow diagram" and "Observational studies should be reported using STROBE guidelines." The journal's transparent peer review model means reviewer comments are published alongside accepted papers, which creates direct accountability for editors who pass through poorly reported manuscripts. The most common desk-rejection trigger: the mandatory reporting checklist PDF is attached but the manuscript text omits required elements.

The protocol was not registered before enrollment, the CONSORT flow diagram is missing, or STROBE items like exposure measurement and sample selection are not described in the Methods. BMJ Open editors are stricter about this than many authors expect for a broad-access journal.

Study design that cannot support the stated conclusions. BMJ Open publishes "any study design" but states submissions must be "scientifically valid." The journal's policy guidance explicitly excludes studies with "unacceptable methodology" regardless of findings. Designs that routinely fail this screen: case series without comparative data, cross-sectional surveys with non-probability samples presented as representative, and before-after studies without control groups that draw causal conclusions.

The framing issue is that authors who submit these designs often present limitations as minor caveats rather than addressing why the design choice is defensible for the research question. The editorial question is whether a reasonable reader could interpret the results without being misled by the study design.

Insufficient ethics and consent documentation. BMJ Open's author instructions require authors to provide "ethics committee approval and patient consent or waiver" as part of submission. For studies in low and middle income countries or studies involving vulnerable populations, the journal applies additional scrutiny. Manuscripts submitted without a named ethics committee, approval reference number, and consent statement in the Methods section regularly receive desk rejection. "Ethics approval was obtained from the institutional review board" without a committee name, country, and reference number is not sufficient.

These are Manusights editorial-pattern observations, not BMJ policy statements. They matter because the 2.5 JIF can tempt authors to think BMJ Open is mainly a safe fallback. It is not. A BMJ Open submission readiness check can verify your reporting guideline implementation against BMJ Open's actual checklist requirements and flag ethics documentation gaps before you submit.

BMJ Open accepts all study types across medicine. That's the official scope. In practice, what fills its pages tells you a lot about where your paper fits:

What gets published most frequently:

• Observational cohort and cross-sectional studies

• Systematic reviews and meta-analyses

• Study protocols (yes, they publish protocols before results exist)

• Qualitative research and mixed-methods studies

• Health services research and implementation science

• Public health and epidemiology studies

What's notable about this list: BMJ Open is one of the few indexed, respectable journals that actively welcomes study protocols and qualitative research. Most medical journals treat these as second-class submissions. BMJ Open treats them as legitimate contributions to the literature, and researchers in these areas know it.

What gets desk-rejected:

• Case reports (BMJ Open doesn't publish them; try BMJ Case Reports)

• Laboratory bench science without clinical relevance

• Studies with no ethics approval documentation

• Papers that don't follow reporting guidelines (STROBE, CONSORT, PRISMA)

• Manuscripts where the sample size doesn't support the conclusions

That last point is worth emphasizing. BMJ Open will publish small studies, but only if you're transparent about the limitations. A study with n=30 that claims generalizable results will get rejected. The same study framed as a pilot with appropriate caveats has a real shot.

BMJ Open pioneered fully open peer review in clinical medicine. Here's what that means in practice:

Every accepted paper gets its reviewer reports published alongside it. Not anonymized summaries. The actual reviewer comments, the editor's decision letters, and the authors' point-by-point responses. All of it, publicly accessible.

This has practical consequences for authors:

1. Reviewers write more carefully. Knowing their comments will be public tends to reduce dismissive or lazy reviews.

1. You can read reviews of similar papers. Before submitting, pull up a few accepted BMJ Open papers in your area and read the reviewer reports. You'll see exactly what editors and reviewers focused on.

1. Your revision quality matters publicly. A sloppy revision response will be visible to anyone who reads your paper. Treat it like a public document.

Reviewer names are published by default, though reviewers can opt out. About 60% choose to sign their reviews.

BMJ currently reports BMJ Open's acceptance rate as 27%. That is accessible compared with elite general medical journals, but it is not generous enough to ignore fit and methods. Papers without ethics documentation, without adherence to reporting guidelines, or with fundamental design flaws get caught early.

Typical timeline:

• Editorial assessment: 1-2 weeks

• Peer review after review invitation: BMJ reports 134 days to first decision with review

• First decision for reviewed papers: plan in months, not weeks

• Revision turnaround: 4-6 weeks (authors' side)

• Total submission to acceptance: depends heavily on review depth and revision complexity

BMJ Open handles about 8,000-10,000 submissions per year and publishes around 3,500-4,000 papers. The volume means the editorial team is experienced at processing manuscripts efficiently, but it also means reviewers are sometimes stretched thin during peak submission periods (January-March and September-November).

BMJ Open is fully open access, so an article processing charge applies unless an institutional agreement, waiver, or discount covers it. BMJ's current author page lists the APC as 2,390 GBP, exclusive of VAT for UK/EU authors and GST for Australian/Indian authors. For comparison, JAMA Network Open and PLOS Medicine usually sit in a higher APC band.

Fee waivers exist for corresponding authors from World Bank-classified low-income countries. Partial waivers can be negotiated for lower-middle-income countries. You need to request the waiver at submission, not after acceptance.

One thing to know: BMJ offers a Read and Publish agreement with many institutions. If your university has an agreement, the APC may be covered entirely. Check with your library before paying out of pocket.

Submit if:

• You have a well-conducted observational study, protocol, or systematic review in clinical medicine

• You want transparent peer review with published reviewer reports

• You want indexing in PubMed, MEDLINE, Scopus, and Web of Science

• Your work is methodologically sound but doesn't aim for high novelty

• You're in public health, health services research, or implementation science

• You need a medical journal that takes qualitative research seriously

For researchers in health services, public health, and primary care, BMJ Open is a workhorse journal. It's where you build a publication record with solid, rigorous clinical work. Nobody will raise an eyebrow at a BMJ Open publication on a CV. It's BMJ-branded, PubMed-indexed, and peer-reviewed.

For researchers in competitive biomedical fields targeting faculty positions at research-intensive institutions, the 2.5 impact factor may not carry enough weight. That's not a judgment on the journal. It's a reality of how hiring committees read CVs. In that situation, consider PLOS Medicine JIF 9.9 or JAMA Network Open JIF 11.7 if the work supports it.

One thing worth knowing: BMJ Open papers do get cited. The journal's h-index of 237 puts it ahead of many journals with higher impact factors. High-volume journals accumulate citations differently than selective ones, and individual BMJ Open papers regularly exceed 50 or 100 citations when the clinical question resonates.

BMJ Open's 2.5 impact factor is exactly what you'd expect from a high-volume, open access medical journal that publishes across all clinical disciplines. It's not trying to compete with The BMJ on selectivity or prestige. It's filling a different role: a transparent, rigorous, accessible home for clinical research that might otherwise sit in a drawer.

The transparent peer review model, reasonable APC, and genuine openness to study types that other journals won't touch (protocols, qualitative research, negative results) make it a practical option. If the work is sound and you don't need a flashy impact factor, BMJ Open delivers what it promises.

The 2.5 impact factor is the number everyone fixates on. Here is the current working picture from BMJ public metrics and Journal Citation Reports context:

Use cited half-life, self-citation, and article-count values from Clarivate Journal Citation Reports when you need formal citation. BMJ's public page is enough for author planning; the database is still the source of record for dossier-grade metric detail.

The content-view figure tells a different story from the JIF. BMJ Open's article-level reach can be high even when the average citation metric is modest. If your paper addresses a clinical question that practitioners, public-health teams, or guideline authors actually search for, BMJ Open's broad indexing and volume can matter more than the headline impact factor.

That is why the metric should be read as a fit filter, not a verdict. BMJ Open is strongest when the study is transparent, useful, and methodologically defensible, even if it is not likely to be cited like a flagship general-medicine paper.

The answer depends on your career stage and what kind of paper you're submitting. Here's the practical breakdown:

Early-career researchers in public health, primary care, or health services research should treat BMJ Open as a reliable workhorse. It builds your PubMed-indexed publication record without the 90%+ rejection rates of top-tier journals. That matters when you need publications for your next contract renewal.

Mid-career researchers should use BMJ Open strategically for protocol registrations and secondary analyses from larger studies. Your RCT goes to BMJ or Lancet; the protocol and your sub-group analyses go to BMJ Open. That's not gaming the system, it's placing each paper where it fits best.

Senior researchers often publish in BMJ Open when they want maximum open-access visibility for public health or implementation science work. At that career stage, the IF doesn't matter, the readership does.

A BMJ Open vs. selective venue scope and fit check can help you figure out whether your paper is competitive at a more selective venue or well-matched to BMJ Open.

• BMJ Open journal profile

• BMJ Open acceptance rate for selectivity, not citation metrics

• BMJ Open submission guide

• See how this journal compares: BMJ British Medical Journal vs. BMJ Open.

• Considering alternatives? See our BMJ vs. JAMA comparison.

• For Scopus-based metrics, see our BMJ Open SJR analysis.

• For a broader assessment, see Is BMJ Open a good journal?

• Considering a submission? Check if your paper is ready for BMJ Open.

Before submitting, a BMJ Open scope and readiness check can catch the fit, framing, and methodology gaps that editors screen for on first read.

Verification note: this BMJ Open page was checked in July 2026 against the 2026 Journal Citation Reports release for 2025 data, BMJ Open public metrics, BMJ Open author guidance, and the journal profile.

BMJ Open's Scopus-style metrics tell a slightly different story than the Journal Citation Reports impact factor alone. Its current About page lists CiteScore 4.1, CiteScore rank 129/669, and SJR 0.93. Those numbers support the same practical point as the 2.5 JIF: BMJ Open has real broad-medicine reach, but the metric panel should be used as venue context rather than as a paper-level quality proxy.

Together, these metrics confirm that BMJ Open's reach is real, even if the 2.5 JIF doesn't look flashy on its own.

Target if:

• The journal's scope matches your paper's primary contribution

• The IF reflects the readership you want to reach

• Your paper can compete at this selectivity level

Consider alternatives if:

• A journal with better scope fit exists even if the IF is lower

• The IF is the primary reason you're considering this journal

• A specialist society journal would give your paper stronger recognition

For a concrete look at the kind of methodology and fit feedback authors receive, review the sample Manusights reports.